AzTrials
AzTrials

Pre DiabetesNCT06668714

Does Co-administration of Lactate Affect Postprandial Nutrient Absorption and Fat Disposition?

A study testing Lactate + mixed meal, PET-scan and Mixed meal with 18F-FTHA in people with Pre Diabetes and Metabolic Syndrome, run by University of Aarhus at 1 site in Denmark.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Aim To investigate the effects of oral lactate administration on nutrient absorption and substrate utilization in individuals with pre-diabetes. Hypothesis The addition of lactate to a meal improves postprandial lipemia and reduces lipid storage in ectopic tissues through delayed absorption and faster removal of… Read more about this study

Who is it for?
Ages 50 years and olderHealthy volunteers can take part
Conditions the study is for
Pre Diabetes, Metabolic Syndrome
What is being tested?
Lactate + mixed meal, PET-scan and Mixed meal with 18F-FTHA
Type of treatment
Surgery or procedure
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
25 participants
Where
1 siteDenmark
Study dates
22 Aug 2024to Jan 2026
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 50 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • 50+ years
  • Written and oral consent
  • HbA1c 39-47 mmol/L

Who cannot join

  • Medicine with an impact on blood glucose and glucose metabolism.
  • Newly started medicine (\<3 months prior to the inclusion time)
  • Medicine changes (\<3 months prior to the inclusion time and planned changes during the trial)
  • Affected screening blood sample as evaluated by PI
  • Hba1c > 47
  • Allergy to paracetamol
Show all 9Show fewer
  • Doesn't speak or understand Danish
  • Special diets
  • The eight healthy individuals will be included by the same criteria except for not having pre-diabetes

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Natasa B Zubanovic, Medical Doctor contact

004561698000

natasa.bz@clin.au.dk

Esben Søndergaard, M.D, Associate Professor contact

esben.sondergaard@clin.au.dk

Denmark1 site, 1 recruiting
  • Aarhus University Hospital

    Aarhus, 8200

    Natasa B Zubanovic, M.D, 004561698000, natasa.bz@clin.au.dk

    Recruiting

Other trials in Denmark

About this study

Aim To investigate the effects of oral lactate administration on nutrient absorption and substrate utilization in individuals with pre-diabetes.

Hypothesis The addition of lactate to a meal improves postprandial lipemia and reduces lipid storage in ectopic tissues through delayed absorption and faster removal of circulating lipids from circulation.

Read the detailed description

A recent study showed that oral lactate administration slowed gastric emptying, increased the feeling of being full, induced satiety, and decreased the anticipated future food intake compared with intravenous administration. This shows that lactate has direct effects in the GI tract, which could improve substrate utilization after meals and thereby improve metabolic health. However, it remains unknown whether oral lactate administration has similar effects in other populations (i.e. individuals with obesity) and in relation to a meal.

To address these potential effects, the investigators aim to implement and validate a new tracer method in Denmark to measure meal fat partitioning using an orally ingested fluorine-labeled fatty acid analog (18F-fluoro-6-thiaheptadecanoic acid, 18F-FTHA) combined with positron emission tomography coupled to computed tomography (PET-CT). In a previous study using the aforementioned method, it has been shown that individuals with an impaired glucose tolerance have increased myocardial fatty acid uptake, not explained by potential confounding factors and that this is associated with a reduced systolic ejection fraction. In a recent study, it was found that subjects with insulin resistance have a higher uptake of free fatty acids in visceral adipose tissue compared with subjects without insulin resistance.

This method will enable the investigators to determine how the addition of lactate to a test meal will affect meal fat partitioning. Previous methods for determining fatty acid partitioning and accumulation have either been limited to only determining the accumulation in non-oxidative tissues or very invasive or difficult to perform, making this the first method to non-invasively simultaneously measure the partitioning of meal fatty acids in all human organs.

Work package 1 (WP1):

The investigators will also include 8 healthy individuals (HbA1c mmol/mol< 39, age 50+ years) as a healthy control group, who will be studied twice in a randomized trial following ingestion of a liquid test meal to determine the differences in meal fat partitioning between insulin-sensitive and insulin-resistant individuals and to determine the intraindividual variation in meal fat partitioning. Furthermore, the extra PET scans performed in the healthy individuals will be used for precise quantification of the radiation exposure with the PET method (dosimetry) and validation of the PET method.

Work package 2 (WP2):

In a randomized, double-blinded placebo-controlled crossover trial, the investigators will investigate the effect of 25 g lactate vs. placebo prior to a liquid test meal, with the addition of 18F-FTHA, on two trial days separated by a minimum of seven days and a maximum of one month. The investigators will include 16 individuals with pre-diabetes (HbA1c 39-47 mmol/mol) and from 50+ years of age.

In a WP3 we will include one healthy participant who will receive 18F-FTHA with water instead of a mixed meal, to evaluate if the tracer can be used for diagnostics of lesions of the thoracic duct when given with water.

The investigators will use paired t-tests analyses for comparing CTR and LAC and independent t-test samples for comparing the individuals with pre-diabetes and the healthy individuals.

Based on the results from a previous study using 18F-FTHA-PET, the investigators will need to include 15 individuals to detect a 15% decrease in meal fat uptake in the heart (α=0.05, β=0.80). To account for potential missing values or failed PET-CT scans, the investigators will include a total of 16 individuals.

Being tested
Placebo + mixed meal, Lactate + mixed meal, PET-scan, Mixed meal with 18F-FTHA
Medical subject headings
Glucose Intolerance, Metabolic Syndrome

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Placebo + mixed mealCombination product

    Placebo (140 mL isoosmotic salt water, NaCl) given 30 minutes before a liquid test meal with the addition of 70 MBq 18F-FTHA = CTR

  • Lactate + mixed mealCombination product

    Lactate (140 mL lactate drink = 25 g D/L-lactate bound to Na) given 30 minutes before a liquid test meal with the addition of 70 MBq 18F-FTHA = LAC The investigators will also use the 18F-FTHA standardized uptake value (SUV) to evaluate dietary fatty acid trapping and distribution, to be able to compare our results with former studies using the 18F-FTHA method.

  • PET-scanRadiation

    Dynamic whole-body PET scan.

  • Mixed meal with 18F-FTHACombination product

    Mixed meal test with the addition of 70 MBq 18F-FTHA

Study groups in NCT06668714
Study groupRoleWhat they receive
Placebo pre-diabetesPlacebo comparatorNot described
Receives: Combination Product: Placebo + mixed meal; Combination Product: Lactate + mixed meal; Radiation: PET-scan
Lactate pre-diabetesExperimentalNot described
Receives: Combination Product: Placebo + mixed meal; Combination Product: Lactate + mixed meal; Radiation: PET-scan
HealthyActive comparatorWe will include 8 healthy, normal-weight individuals (BMI 20-25 kg/m2, age 50+ years) as a healthy control group, who will be studied twice following ingestion of a liquid test meal to determine the differences in meal fat partitioning between insulin-sensitive and insulin-resistant individuals and to determine the intraindividual variation in meal fat partitioning. Furthermore, the extra PET scans performed in the healthy individuals will be used for precise quantification of the radiation exposure with the PET method (dosimetry) and validation of the PET method.
Receives: Radiation: PET-scan; Combination Product: Mixed meal with 18F-FTHA

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Difference in meal fat uptake in heart tissue between CTR and LAC following a liquid test meal

    The investigators will use a dynamic whole-body PET scan to determine dietary fatty acid trapping and distribution by measuring available 18F-FTHA-tracer in blood coupled with measurement of radioactivity in different organs.

    The investigators will also use the 18F-FTHA standardized uptake value (SUV) to evaluate dietary fatty acid trapping and distribution, to be able to compare our results with former studies using the 18F-FTHA method.

    Measured: 5-6 hours

Secondary outcomes (4)
  1. Difference in meal fat uptake in skeletal muscle, liver, subcutaneous fat, heart and visceral fat

    We will use a dynamic whole-body PET scan to determine dietary fatty acid trapping and distribution by measuring available 18F-FTHA-tracer in blood coupled with measurement of radioactivity in different organs.

    We will also use the 18F-FTHA standardized uptake value (SUV) to evaluate dietary fatty acid trapping and distribution, to be able to compare our results with former studies using the 18F-FTHA method.

    Measured: 7 hours

  2. Difference in absorption rate and distribution of free fatty acids.

    We will draw blood samples from arterialized blood from a perifery venous catheter and measure the concentration of free fatty acids on the two trial days.

    Measured: 7 hours

  3. Difference in subjective appetite sensation

    Subjective appetite sensation will be quantified using the appetite questionnaires consisting of a visual analog scale.

    Measured: 7 hours

  4. Difference in ventricular emptying rate

    We will use the acetaminophen test to evaluate ventricular emptying rate. The participants will drink 1500 mg paracetamol together with the mixed meal, and afterwards blood samples will be drawn and the concentration of acetaminophen will be measured during the trial day and compared between the two trial days.

    Measured: 7 hours

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted31 Oct 2024
  2. Study start22 Aug 2024
  3. Primary completionJan 2026 (estimated)
  4. Study completionJan 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Randomised
Intervention model
Crossover
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
25 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06668714
Sponsor's protocol ID
LAMETA-PET
Status last verified
Jun 2025
First submitted
17 Sep 2024
Last updated
19 Jun 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing Lactate + mixed meal, PET-scan and Mixed meal with 18F-FTHA in people with Pre Diabetes and Metabolic Syndrome, run by University of Aarhus at 1 site in Denmark.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 19 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Natasa B Zubanovic, Medical Doctor (004561698000, natasa.bz@clin.au.dk), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Difference in meal fat uptake in heart tissue between CTR and LAC following a liquid test meal (time frame: 5-6 hours). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Jun 2025.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in